# Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning

> **NCT01572662** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 201 (actual)

## Conditions studied

- Leukemia
- Acute Myeloid Leukemia
- Acute Lymphocytic Leukemia
- Chronic Myeloid Leukemia
- Chronic Lymphocytic Leukemia
- Myeloproliferative Diseases
- Non-Hodgkins Lymphoma
- Hodgkins Lymphoma
- Multiple Myeloma
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Fludarabine monophosphate
- **DRUG:** Busulfan
- **PROCEDURE:** Stem Cell Infusion
- **DRUG:** Tacrolimus
- **DRUG:** Methotrexate
- **DRUG:** G-CSF

## Key facts

- **NCT ID:** NCT01572662
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-11
- **Primary completion:** 2022-08-11
- **Final completion:** 2022-08-11
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2023-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01572662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01572662, "Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT01572662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*